Synopsis
Synopsis
0
CEP/COS
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 13496, Sm
2. Hcl, Lurasidone
3. Hydrochloride, Lurasidone
4. Latuda
5. Lurasidone
6. Lurasidone Hcl
7. N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
8. Sm 13,496
9. Sm 13496
10. Sm-13,496
11. Sm-13496
12. Sm13,496
13. Sm13496
1. Lurasidone Hcl
2. 367514-88-3
3. Latuda
4. Sm-13496
5. Lurasidone Hydrochloride [usan]
6. Sm 13496
7. Chebi:70732
8. O0p4i5851i
9. Lurasidonhydrochloride
10. (1s,2r,6s,7r)-4-[[(1r,2r)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride
11. (3ar,4s,7r,7as)-2-(((1r,2r)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1h-4,7-methanoisoindole-1,3(2h)-dione Hydrochloride
12. (1r,2s,6r,7s)-4-{[(1r,2r)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0^{2,6}]decane-3,5-dione Hydrochloride
13. 4,7-methano-1h-isoindole-1,3(2h)-dione, 2-(((1r,2r)-2-((4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)methyl)cyclohexyl)methyl)hexahydro-, Monohydrochloride, (3ar,4s,7r,7as)-
14. Unii-o0p4i5851i
15. Latuda (tn)
16. Lurasidone Monohydrochloride
17. Lurasidone-d8 Hydrochloride
18. Sm-13496 (hydrochloride)
19. Schembl1534132
20. Chembl1615372
21. Dtxsid401027714
22. Lurasidone Hydrochloride (jan/usan)
23. Lurasidone Hydrochloride [mi]
24. S3044
25. Smp-13496
26. Lurasidone Hydrochloride [jan]
27. Akos022185856
28. Ex-3125
29. Mk-3756
30. Lurasidone Hydrochloride [mart.]
31. Lurasidone Hydrochloride [vandf]
32. Lurasidone Hydrochloride [who-dd]
33. As-35074
34. Lurasidone Hydrochloride, >=98% (hplc)
35. Lurasidone Hydrochloride [orange Book]
36. D04820
37. Q27882070
38. (3ar,4s,7r,7as)-2-((1r,2r)-2-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione, Hydrochloride
39. (3ar,4s,7r,7as)-2-{(1r,2r)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2h-isoindole-1,3-dione Hydrochloride
40. (3ar,4s,7r,7as)-2-{[(1r,2r)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}hexahydro-1h-4,7-methanoisoindole-1,3(2h)-dione Hydrochloride
41. 4-(1,2-benzothiazol-3-yl)-1-{[(1r,2r)-2-{[(3ar,4s,7r,7as)-1,3-dioxooctahydro-2h-4,7-methanoisoindol-2-yl]methyl}cyclohexyl]methyl}piperazin-1-ium Chloride
42. Lurasidone Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 529.1 g/mol |
|---|---|
| Molecular Formula | C28H37ClN4O2S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 528.2325753 g/mol |
| Monoisotopic Mass | 528.2325753 g/mol |
| Topological Polar Surface Area | 85 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 804 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Latuda |
| PubMed Health | Lurasidone (By mouth) |
| Drug Classes | Antipsychotic, Central Nervous System Agent |
| Drug Label | LATUDA is a psychotropic agent belonging to the chemical class of benzoisothiazol derivatives. Its chemical name is (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3... |
| Active Ingredient | Lurasidone hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 120mg; 60mg; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Sunovion Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Latuda |
| PubMed Health | Lurasidone (By mouth) |
| Drug Classes | Antipsychotic, Central Nervous System Agent |
| Drug Label | LATUDA is a psychotropic agent belonging to the chemical class of benzoisothiazol derivatives. Its chemical name is (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3... |
| Active Ingredient | Lurasidone hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 120mg; 60mg; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Sunovion Pharms |
Treatment of schizophrenia in adults aged 18 years and over.
Treatment of schizophrenia
Adrenergic alpha-2 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Antagonists.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine D2 Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)
Serotonin 5-HT2 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)
N05AE05
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 120MG
USFDA APPLICATION NUMBER - 200603
DOSAGE - TABLET;ORAL - 20MG
USFDA APPLICATION NUMBER - 200603
DOSAGE - TABLET;ORAL - 40MG
USFDA APPLICATION NUMBER - 200603
DOSAGE - TABLET;ORAL - 60MG
USFDA APPLICATION NUMBER - 200603
DOSAGE - TABLET;ORAL - 80MG
USFDA APPLICATION NUMBER - 200603
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Disintegrants & Superdisintegrants
Direct Compression
Chewable & Orodispersible Aids
Taste Masking
Lubricants & Glidants
Co-Processed Excipients
Granulation
Parenteral
Thickeners and Stabilizers
Coating Systems & Additives
Solubilizers
Controlled & Modified Release
Rheology Modifiers
Emulsifying Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
18
PharmaCompass offers a list of Lurasidone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lurasidone manufacturer or Lurasidone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lurasidone manufacturer or Lurasidone supplier.
PharmaCompass also assists you with knowing the Lurasidone API Price utilized in the formulation of products. Lurasidone API Price is not always fixed or binding as the Lurasidone Price is obtained through a variety of data sources. The Lurasidone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lurasidone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lurasidone, including repackagers and relabelers. The FDA regulates Lurasidone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lurasidone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lurasidone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lurasidone supplier is an individual or a company that provides Lurasidone active pharmaceutical ingredient (API) or Lurasidone finished formulations upon request. The Lurasidone suppliers may include Lurasidone API manufacturers, exporters, distributors and traders.
click here to find a list of Lurasidone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lurasidone DMF (Drug Master File) is a document detailing the whole manufacturing process of Lurasidone active pharmaceutical ingredient (API) in detail. Different forms of Lurasidone DMFs exist exist since differing nations have different regulations, such as Lurasidone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lurasidone DMF submitted to regulatory agencies in the US is known as a USDMF. Lurasidone USDMF includes data on Lurasidone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lurasidone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lurasidone suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lurasidone Drug Master File in Japan (Lurasidone JDMF) empowers Lurasidone API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lurasidone JDMF during the approval evaluation for pharmaceutical products. At the time of Lurasidone JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lurasidone suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lurasidone Drug Master File in Korea (Lurasidone KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lurasidone. The MFDS reviews the Lurasidone KDMF as part of the drug registration process and uses the information provided in the Lurasidone KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lurasidone KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lurasidone API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lurasidone suppliers with KDMF on PharmaCompass.
A Lurasidone written confirmation (Lurasidone WC) is an official document issued by a regulatory agency to a Lurasidone manufacturer, verifying that the manufacturing facility of a Lurasidone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lurasidone APIs or Lurasidone finished pharmaceutical products to another nation, regulatory agencies frequently require a Lurasidone WC (written confirmation) as part of the regulatory process.
click here to find a list of Lurasidone suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lurasidone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lurasidone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lurasidone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lurasidone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lurasidone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lurasidone suppliers with NDC on PharmaCompass.
Lurasidone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lurasidone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lurasidone GMP manufacturer or Lurasidone GMP API supplier for your needs.
A Lurasidone CoA (Certificate of Analysis) is a formal document that attests to Lurasidone's compliance with Lurasidone specifications and serves as a tool for batch-level quality control.
Lurasidone CoA mostly includes findings from lab analyses of a specific batch. For each Lurasidone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lurasidone may be tested according to a variety of international standards, such as European Pharmacopoeia (Lurasidone EP), Lurasidone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lurasidone USP).
